FDAapproval95% confidence
FDA Drug Competition Action Plan | Improving the efficiency of the generic drug development, review, and approval process
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (prostate cancer) as Roche; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
By clarifying FDA’s regulatory expectations for new entrants and experienced drug developers alike, FDA is supporting prospective generic drug developers and improving the overall quality of ANDAs submitted to the Agency for approval.
Supporting Context
- Therapeutic area
- Oncology · Prostate Cancer
- Sub-indication
- Prostate Cancer
Related signal: Roche's VENTANA PTEN Assay Receives FDA Approval for Prostate Cancer Companion Diagnostic